Moderna, Inc. (MRNA) KPIs and segments
Close on Nov 18, 2026Market cap $78.57BP/E –Yield –
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Moderna · năm tài chính kết thúc Calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q2 2026 ended June 30, 2026)
Nhìn nhanh KPI của Moderna: 30 chỉ số vận hành, trong đó có Net product sales — Total commercial vaccines, Other revenue và Consolidated total revenue by customer geography, lấy từ 93 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net product sales($M) | 94 | 352 | 646 | 973 | 114 | 86 | 938 | 1,820 | 184 | 167 | 2,793 | 1,757 | |
COVID($M) | 91 | 345 | 642 | 971 | 114 | 84 | 923 | 1,810 | 184 | 167 | 2,793 | 1,757 | |
Other revenue($M) | 51 | 37 | 32 | 43 | 28 | 22 | 28 | 42 | 57 | 0 | 18 | 74 | |
Stand-ready manufacturing revenue($M) | 31 | 32 | 17 | 12 | |||||||||
Collaboration revenue (Note 5)($M) | 15 | 5 | 1 | 7 | 4 | 1 | 13 | 28 | 7 | 0 | 20 | 30 | |
Licensing and royalty revenue($M) | 3 | 0 | 2 | 2 | 8 | 5 | 7 | 30 | 0 | 0 | 0 | ||
RSV($M) | 3 | 7 | 4 | 2 | 0 | 2 | 15 | 10 | 0 | 0 | 0 | 0 | |
Grant revenue($M) | 2 | 0 | 2 | 14 | 5 | 1 | 10 | 7 | 20 | 0 | 44 | ||
United States($M) | 70 | 73 | 264 | 782 | 88 | 31 | 249 | 1,215 | 162 | 100 | 804 | 913 | |
Europe($M) | 16 | 239 | 34 | 16 | 0 | 0 | 292 | 281 | 0 | 0 | 614 | 103 | |
Rest of world($M) | 8 | 40 | 348 | 175 | 26 | 55 | 397 | 324 | 22 | 67 | 1,375 | 741 | |
Rentable area1 | |||||||||||||
Cambridge leases(triệu ft²) | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.7 | 0.7 | 0.3 | 0.3 | ||||
Net product sales — Total commercial vaccines ($M)($M)3 | 94 | 352 | 646 | 973 | 114 | 86 | 938 | 1,820 | 184 | 167 | 2,793 | 1,757 | |
COVID-19 vaccines (Spikevax / mRNA-1273 & mNEXSPIKE / mRNA-1283) — Net product sales ($M)($M) | 91 | 345 | 642 | 971 | 114 | 84 | 923 | 1,810 | 184 | 167 | 2,793 | 1,757 | |
Net product sales — United States ($M)($M) | 70 | 73 | 264 | 782 | 88 | 31 | 249 | 1,215 | 162 | 100 | 804 | 913 | |
Approved commercial products on market (products) | 4.00 | 3.00 | 3.00 | 3.00 | 3.00 | 2.00 | 2.00 | 2.00 | 2.00 | ||||
Other revenue — Stand-ready manufacturing, grants, collaborations & royalties ($M)($M)2 | 51 | 37 | 32 | 43 | 28 | 22 | 28 | 42 | 57 | 0 | 18 | 74 | |
Grant revenue — Total (BARDA, DARPA, CEPI & Gates Foundation) ($M)($M)1 | 2 | 0 | 2 | 14 | 5 | 1 | 10 | 7 | 20 | 0 | -2 | 44 | |
BARDA grant revenue (mRNA-1273 & pandemic influenza) ($M)($M) | 0 | 44 | |||||||||||
Collaboration revenue — Total ($M)($M)2 | 15 | 5 | 1 | 7 | 4 | 1 | 13 | 28 | 7 | 0 | 20 | 30 | |
Merck collaboration revenue ($M)($M) | 0 | 0 | |||||||||||
AstraZeneca collaboration revenue ($M)($M) | 0 | 0 | |||||||||||
Consolidated total revenue by customer geography ($M)($M) | 145 | 389 | 678 | 1,016 | 142 | 108 | 966 | 1,862 | 241 | 167 | 2,811 | 1,831 | |
Gross product sales (before gross-to-net variable consideration deductions) ($M)($M)2 | 122 | 350 | 1,053 | 1,971 | 176 | 105 | 1,140 | 2,964 | 191 | 222 | 3,662 | 2,420 | |
Total gross-to-net (GTN) provisions & variable consideration deductions ($M)($M)4 | 28 | -2 | 407 | 998 | 62 | 19 | 202 | 1,144 | 7 | 55 | 869 | 663 | |
GTN provision — Chargebacks, discounts and distribution fees ($M)($M) | 50 | -11 | 191 | 762 | 62 | 22 | 88 | 1,053 | -22 | 22 | 497 | 479 | |
GTN provision — Product sales returns ($M)($M) | 1 | 0 | 14 | 11 | 3 | 0 | 14 | 29 | |||||
GTN provision related to sales made in current period ($M)($M) | 14 | 9 | 237 | 175 | 16 | 8 | 118 | ||||||
GTN provision adjustment related to sales made in prior periods ($M)($M) | -36 | 0 | -21 | 7 | 16 | 11 | 4 | ||||||
Actual GTN payments, credits and deductions applied against reserves ($M)($M)1 | 49 | 49 | 94 | 109 | 34 | 42 | 268 | 360 | 25 | 51 | 1,207 | 282 | |
Actual returns/credits applied related to prior-period sales ($M)($M) | 26 | 48 | 119 | 107 | 26 | 30 | 133 | 213 | 36 | 15 | |||
Balance sheet GTN reserves — Refund liability (sales returns & rebates reserve) ($M)($M)4 | 421 | 470 | 509 | 426 | 308 | 337 | 370 | 403 | 554 | 574 | 556 | 184 | |
Accounts receivable, gross (before chargeback allowances) ($M)($M) | 120 | 203 | 368 | 2,024 | 260 | 249 | 698 | 2,732 | 492 | 422 | 1,584 | 2,360 | |
Allowance for chargebacks and cash discounts (contra-AR) ($M)($M) | 97 | 126 | 181 | 975 | 212 | -171 | 340 | -1,168 | -329 | -285 | -692 | -479 | |
Allowance for expected credit losses ($M)($M) | 6 | 6 | 3 | 3 | 12 | 0 | 0 | ||||||
Accounts receivable, net ($M)($M) | 17 | 71 | 184 | 1,046 | 36 | 78 | 358 | 1,564 | 163 | 137 | 892 | 1,866 | |
Deferred revenue — Total customer deposits & Advance Purchase Agreements (APAs) ($M)($M)7 | 442 | 256 | 252 | 320 | 283 | 183 | 211 | 474 | 797 | 617 | 651 | 1,538 | |
Deferred revenue — Current ($M)($M) | 295 | 102 | 99 | 163 | 218 | 125 | 153 | 379 | 702 | 559 | 568 | 1,372 | |
Deferred revenue — Non-current ($M)($M) | 147 | 154 | 153 | 157 | 65 | 58 | 58 | 95 | 95 | 58 | 83 | 166 | |
Deferred revenue — Product sales (sovereign APAs & customer deposits) ($M)($M) | 265 | 95 | 107 | 144 | 221 | 154 | 188 | 443 | 740 | 580 | 613 | 1,493 | |
Deferred revenue — Stand-ready manufacturing, collaborations & grants ($M)($M) | 177 | 161 | 145 | 176 | 62 | 29 | 23 | 20 | |||||
Deferred revenue — Collaboration arrangements (legacy disaggregation) ($M)($M) | 6 | 7 | 33 | 33 | 34 | 41 | |||||||
Deferred revenue — Government grants (legacy disaggregation) ($M)($M) | 9 | 11 | 4 | 4 | 4 | 4 | |||||||
Revenue recognized from beginning-of-year deferred revenue balance ($M)($M)4 | 235 | 53 | 26 | 146 | 134 | 14 | 5 | 37 | 205 | 17 | 320 | 88 | |
Recognized from beginning deferred revenue — Product sales ($M)($M) | 171 | 0 | 24 | 0 | 84 | 0 | 1 | 28 | 182 | 14 | 308 | 80 | |
Recognized from beginning deferred revenue — Other revenue ($M)($M) | 64 | 53 | 2 | 146 | 50 | 14 | |||||||
Recognized from beginning deferred revenue — Collaborations (legacy) ($M)($M) | 5 | 1 | 3 | 3 | 12 | 6 | |||||||
Recognized from beginning deferred revenue — Grants (legacy) ($M)($M) | -1 | 8 | 0 | 0 | 0 | 2 | |||||||
Cost of sales — Total ($M)($M)6 | 93 | 955 | 452 | 207 | 119 | 90 | 739 | 514 | 115 | 96 | 929 | 2,241 | |
Cost of sales as % of net product sales (%)(%) | 74.0% | 249.0% | 21.0% | 105.0% | 104.0% | 79.0% | 28.0% | 62.0% | 58.0% | 33.0% | 128.0% | ||
Third-party royalties & milestone payments included in cost of sales ($M)($M) | 11 | 895 | 34 | 43 | 6 | 5 | 45 | 92 | 10 | 8 | 125 | 78 | |
Inventory write-downs (excess & expiring shelf-life vaccines/raw materials) ($M)($M) | 41 | 38 | 144 | 67 | 38 | 42 | 193 | 214 | 14 | 30 | 300 | 1,300 | |
Unutilized manufacturing capacity & CMO wind-down charges ($M)($M) | 23 | 52 | 21 | 259 | 27 | 55 | 27 | 169 | |||||
Losses on firm purchase commitments & CMO cancellation fees ($M)($M) | 0 | 0 | 0 | 7 | 7 | 10 | 39 | 21 | 0 | 0 | 0 | 0 | |
Stock-based compensation expense in cost of sales ($M)($M) | 13 | 3 | 5 | 7 | 7 | 7 | 6 | 6 | 6 | 7 | 9 | 7 | |
Inventory, net — Total on balance sheet ($M)($M)6 | 280 | 146 | 153 | 332 | 240 | 128 | 117 | 412 | 399 | 295 | 202 | 487 | |
Raw materials inventory ($M)($M) | 117 | 94 | 91 | 85 | 83 | 75 | 63 | 171 | 199 | 215 | 163 | 149 | |
Work in process (drug substance & bulk formulated mRNA) inventory ($M)($M) | 97 | 38 | 29 | 119 | 112 | 39 | 26 | 95 | 166 | 60 | 15 | 61 | |
Finished goods (filled & packaged vaccine doses) inventory ($M)($M) | 66 | 14 | 33 | 128 | 45 | 14 | 28 | 146 | 34 | 20 | 24 | 277 | |
Gross inventory (including zero-cost raw materials awaiting destruction) ($M)($M) | 361 | 263 | 267 | 447 | 367 | 262 | 267 | 477 | 560 | 440 | 372 | 698 | |
Prepaid manufacturing materials & CMO advances, current ($M)($M) | 70 | 55 | 61 | 77 | 96 | 84 | 106 | 193 | 111 | 123 | 168 | 61 | |
Accounts payable — Raw materials & manufacturing suppliers ($M)($M) | 44 | 27 | 30 | 46 | 30 | 28 | 41 | 57 | 42 | 36 | 27 | 71 | |
Development pipeline — Total active mRNA development programs (programs)2 | 36.00 | 35.00 | 35.00 | 40.00 | 39.00 | 41.00 | 44.00 | 45.00 | 47.00 | 47.00 | 45.00 | 43.00 | |
Development candidates in pipeline (candidates) | 26.00 | 25.00 | 25.00 | 30.00 | 30.00 | 31.00 | 34.00 | 36.00 | 40.00 | 40.00 | 42.00 | 41.00 | |
Development programs currently in clinical studies (programs) | 36.00 | 35.00 | 35.00 | 37.00 | 35.00 | 38.00 | 41.00 | 42.00 | 43.00 | 43.00 | 40.00 | 38.00 | |
ClinicalTrials.gov registry — Cumulative Moderna-sponsored studies (studies)9 | 139.00 | 137.00 | 135.00 | 131.00 | 127.00 | 125.00 | 122.00 | 117.00 | 113.00 | 110.00 | 105.00 | 100.00 | |
Cumulative interventional clinical trials (trials) | 116.00 | 114.00 | 112.00 | 108.00 | 104.00 | 102.00 | 99.00 | 94.00 | 90.00 | 87.00 | 83.00 | 78.00 | |
Cumulative Phase 1 clinical trials (trials) | 34.00 | 34.00 | 33.00 | 32.00 | 31.00 | 31.00 | 30.00 | 29.00 | 29.00 | 29.00 | 28.00 | 28.00 | |
Cumulative Phase 2 clinical trials (trials) | 46.00 | 45.00 | 45.00 | 44.00 | 43.00 | 41.00 | 39.00 | 39.00 | 38.00 | 37.00 | 34.00 | 32.00 | |
Cumulative Phase 3 registrational clinical trials (trials) | 34.00 | 33.00 | 32.00 | 30.00 | 28.00 | 28.00 | 28.00 | 25.00 | 22.00 | 20.00 | 20.00 | 17.00 | |
Cumulative respiratory vaccine trials (COVID-19, RSV, Flu, Combo) (trials) | 54.00 | 54.00 | 53.00 | 51.00 | 49.00 | 49.00 | 48.00 | 46.00 | 43.00 | 42.00 | 42.00 | 38.00 | |
Cumulative oncology & individualized neoantigen therapy (mRNA-4157) trials (trials) | 19.00 | 18.00 | 18.00 | 17.00 | 16.00 | 15.00 | 13.00 | 12.00 | 12.00 | 10.00 | 9.00 | 8.00 | |
Cumulative latent virus, rare disease & other therapeutic trials (trials) | 43.00 | 42.00 | 41.00 | 40.00 | 39.00 | 38.00 | 38.00 | 36.00 | 35.00 | 35.00 | 32.00 | 32.00 | |
Cumulative participant enrollment across interventional clinical trials (participants)1 | 469,580.00 | 468,338.00 | 464,168.00 | 392,832.00 | 391,288.00 | 390,948.00 | 389,278.00 | 270,934.00 | 190,190.00 | 189,655.00 | 189,381.00 | 178,590.00 | |
Cumulative participant enrollment in Phase 3 registrational trials (participants) | 330,807.00 | 329,931.00 | 325,881.00 | 254,821.00 | 253,482.00 | 253,482.00 | 253,482.00 | 249,345.00 | 169,532.00 | 169,269.00 | 169,269.00 | 159,187.00 | |
Newly initiated Moderna clinical studies in period (studies)2 | 2.00 | 2.00 | 4.00 | 4.00 | 2.00 | 3.00 | 5.00 | 4.00 | 3.00 | 5.00 | 5.00 | 9.00 | |
Newly initiated interventional clinical trials in period (trials) | 2.00 | 2.00 | 4.00 | 4.00 | 2.00 | 3.00 | 5.00 | 4.00 | 3.00 | 4.00 | 5.00 | 8.00 | |
Target/actual participant enrollment in newly initiated interventional trials (participants) | 1,242.00 | 4,170.00 | 71,336.00 | 1,544.00 | 340.00 | 1,670.00 | 118,344.00 | 80,744.00 | 535.00 | 274.00 | 10,791.00 | 7,361.00 | |
Research and development expenses — Total GAAP ($M)($M)1 | 651 | 649 | 775 | 801 | 700 | 856 | 1,122 | 1,137 | 1,221 | 1,063 | 1,406 | 1,160 | |
Stock-based compensation expense in R&D ($M)($M) | 64 | 64 | 67 | 74 | 81 | 69 | 68 | 69 | 67 | 60 | 42 | 40 | |
Strategic collaborations — Merck (intismeran autogene / mRNA-4157) gross R&D incurred ($M)($M)3 | 97 | 101 | 103 | 101 | 99 | 104 | 110 | 109 | 95 | 76 | 62 | 53 | |
Merck (mRNA-4157) 50/50 cost share — Reimbursement recognized as contra-R&D ($M)($M) | 1 | 1 | 5 | 1 | 6 | 12 | 27 | 25 | 33 | 24 | 68 | 16 | |
Collaborative arrangements receivable, current ($M)($M) | 0 | 1 | 13 | 9 | 20 | 26 | 58 | 99 | 73 | 59 | 61 | 44 | |
Research and development partners payable, current ($M)($M) | 14 | 0 | 43 | 0 | 0 | 0 | 58 | 0 | |||||
Strategic collaborations — Blackstone Life Sciences (influenza) funding recognized as contra-R&D ($M)($M)2 | 24 | 50 | 66 | 25 | 160 | 90 | 232 | 30 | 0 | 0 | |||
Reimbursement liability to R&D funding partners, current ($M)($M) | 58 | 111 | 84 | 0 | 118 | 179 | 103 | 119 | 0 | ||||
Upfront licensing & in-process R&D (IPR&D) milestone payments ($M)($M) | 11 | 895 | 34 | 43 | 6 | 5 | 45 | 92 | 10 | 8 | 125 | 78 | |
Property, plant and equipment, net ($M)($M)4 | 2,059 | 2,086 | 2,134 | 2,126 | 2,169 | 2,212 | 2,196 | 2,381 | 2,196 | 2,063 | 1,945 | 1,952 | |
Property, plant and equipment, gross ($M)($M)8 | 2,908 | 2,880 | 2,871 | 2,797 | 2,792 | 2,778 | 2,723 | 2,932 | 2,700 | 2,528 | 2,378 | 3,024 | |
Manufacturing and laboratory equipment, gross ($M)($M) | 550 | 543 | 542 | 493 | 433 | 361 | 344 | 384 | 355 | 355 | 345 | 334 | |
Construction in progress (MITC facilities & Norwood expansion), gross ($M)($M) | 279 | 268 | 298 | 350 | 913 | 1,078 | 1,057 | 975 | 961 | 865 | 860 | 720 | |
Leasehold improvements, gross ($M)($M) | 409 | 408 | 403 | 359 | 264 | 208 | 207 | 674 | 664 | 642 | 522 | 490 | |
Finance lease right-of-use assets, gross ($M)($M) | 132 | 132 | 132 | 132 | 132 | 132 | 132 | 604 | 529 | 529 | 529 | 1,367 | |
Buildings and site improvements, gross ($M)($M) | 1,216 | 1,216 | 1,183 | 1,160 | 798 | 759 | 743 | 87 | 0 | ||||
Land, gross ($M)($M) | 77 | 77 | 78 | 78 | 59 | 59 | 59 | 22 | 22 | 32 | 22 | 32 | |
Computer equipment and software, gross ($M)($M) | 205 | 196 | 196 | 188 | 161 | 150 | 150 | 153 | 136 | 73 | 74 | 55 | |
Furniture and fixtures, gross ($M)($M) | 40 | 40 | 39 | 37 | 32 | 31 | 31 | 33 | 33 | 32 | 26 | 26 | |
Accumulated depreciation and amortization ($M)($M) | 849 | 794 | 737 | 671 | 623 | 566 | 527 | 551 | 504 | 465 | 433 | 1,072 | |
Capital expenditures — Purchases of property and equipment ($M)($M) | 37 | 62 | 39 | 33 | 3 | 117 | 522 | 151 | 182 | 196 | 220 | 140 | |
Non-cash PP&E additions included in accounts payable and accrued liabilities ($M)($M) | 1 | 35 | 41 | -5 | -3 | 50 | 19 | -8 | -5 | 91 | -18 | 43 | |
Real estate footprint — Leased space in Cambridge, Massachusetts (sq ft)1 | 462,000.00 | 462,000.00 | 462,000.00 | 462,000.00 | 462,000.00 | 462,000.00 | 462,000.00 | 667,000.00 | 667,000.00 | 276,000.00 | 292,000.00 | 292,000.00 | |
Norwood, Massachusetts manufacturing & technical development campus (sq ft) | 722,000.00 | 722,000.00 | 722,000.00 | 722,000.00 | 722,000.00 | 686,000.00 | 686,000.00 | 686,000.00 | 686,000.00 | 686,000.00 | |||
Total operating and finance lease liabilities ($M)($M)5 | 696 | 708 | 715 | 734 | 741 | 745 | 747 | 1,355 | 1,269 | 1,237 | 1,243 | 1,455 | |
Lease liabilities — Current ($M)($M) | 52 | 50 | 42 | 48 | 43 | 43 | 37 | 51 | 25 | 25 | 25 | 183 | |
Lease liabilities — Non-current ($M)($M) | 644 | 658 | 673 | 686 | 698 | 702 | 710 | 1,304 | 1,244 | 1,212 | 1,218 | 1,272 | |
Operating lease liabilities ($M)($M) | 659 | 664 | 670 | 677 | 682 | 682 | 685 | 700 | 693 | 662 | 668 | 730 | |
Finance lease liabilities ($M)($M) | 37 | 44 | 45 | 57 | 59 | 63 | 62 | 655 | 576 | 575 | 575 | 725 | |
Total operating and finance lease right-of-use (ROU) assets ($M)($M) | 727 | 742 | 761 | 785 | 803 | 811 | 824 | 1,282 | 1,205 | 1,130 | 1,149 | 1,366 | |
Minimum unconditional purchase obligations — Supply & manufacturing agreements ($M)4 | |||||||||||||
Accrued liabilities — External development & clinical/manufacturing operations ($M)($M)5 | 78 | 81 | 106 | 94 | 108 | 120 | 120 | 80 | 90 | 141 | 140 | 110 | |
Accrued liabilities — Clinical trials ($M)($M) | 38 | 46 | 20 | 30 | 38 | 88 | 94 | 51 | 96 | 136 | 175 | 263 | |
Accrued liabilities — Manufacturing ($M)($M) | 86 | 79 | 140 | 113 | 152 | 128 | 109 | 137 | 119 | 112 | 167 | 779 | |
Accrued liabilities — Third-party royalties ($M)($M) | 954 | 967 | 31 | 42 | 6 | 5 | 46 | 92 | 10 | 8 | 122 | 78 | |
Accrued liabilities — Commercial operations ($M)($M) | 18 | 16 | 23 | 21 | 24 | 24 | 45 | 36 | 32 | 40 | 56 | 137 | |
Accrued liabilities — Other external goods and services ($M)($M) | 58 | 82 | 57 | 53 | 63 | 82 | 131 | 177 | 109 | 135 | 137 | 145 | |
Accrued liabilities — Employee compensation and benefits ($M)($M) | 192 | 108 | 420 | 310 | 197 | 120 | 312 | 244 | 187 | 95 | 245 | 251 | |
Accrued liabilities — Property and equipment ($M)($M) | 18 | 31 | 45 | 31 | 47 | 49 | 99 | 78 | 93 | 95 | 94 | 108 | |
Patent infringement & settlement indemnification accrual ($M)($M)1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Patent litigation settlement & indemnification expense recognized in period ($M)($M) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Available-for-sale (AFS) marketable securities, current — Fair value ($M)($M)9 | 3,415 | 3,297 | 3,204 | 3,372 | 3,852 | 4,352 | 5,098 | 5,223 | 6,010 | 6,472 | 5,697 | 4,641 | |
Available-for-sale (AFS) marketable securities, non-current — Fair value ($M)($M) | 1,772 | 2,251 | 2,336 | 2,143 | 2,374 | 2,418 | 2,494 | 2,335 | 2,326 | 3,638 | 4,677 | 5,273 | |
Cash equivalents & AFS marketable debt securities — Total amortized cost ($M)($M) | 5,202 | 5,556 | 5,533 | 5,510 | 6,227 | 6,775 | 7,614 | 7,577 | 8,429 | 10,232 | 10,519 | 10,182 | |
AFS debt securities maturing within 1 year — Fair value ($M)($M) | 3,415 | 3,297 | 3,204 | 3,372 | 3,852 | 4,352 | 5,098 | 5,223 | 6,010 | 6,472 | 5,697 | 4,641 | |
AFS debt securities maturing in 1 to 5 years — Fair value ($M)($M) | 1,772 | 2,251 | 2,336 | 2,143 | 2,374 | 2,418 | 2,494 | 2,335 | 2,326 | 3,638 | 4,677 | 5,273 | |
Portfolio by asset class — U.S. Treasury & government agency debt securities ($M)($M) | 55 | 56 | 66 | 30 | 73 | 92 | 138 | 152 | 194 | 222 | 208 | 150 | |
Portfolio by asset class — Corporate debt securities & commercial paper ($M)($M) | 2,440 | 2,978 | 3,163 | 2,525 | 2,899 | 3,367 | 3,763 | 3,975 | 4,286 | 5,072 | 5,480 | 5,012 | |
Portfolio by asset class — Money market funds ($M)($M) | 1,447 | 595 | 963 | 473 | 649 | 558 | 1,195 | 530 | 647 | 709 | 1,572 | 1,438 | |
Portfolio by asset class — Certificates of deposit & time deposits ($M)($M) | 53 | 61 | 91 | 103 | 90 | 102 | 52 | 27 | 29 | 75 | 27 | 30 | |
Portfolio by asset class — Marketable equity securities ($M)($M) | 2 | 2 | 6 | 9 | 6 | 6 | 14 | 23 | 31 | 53 | 24 | 44 | |
Stock-based compensation (SBC) expense — Total ($M)($M)6 | 120 | 104 | 113 | 125 | 130 | 115 | 104 | 112 | 112 | 101 | 79 | 77 | |
SBC by award type — Stock options ($M)($M) | 29 | 24 | 35 | 37 | 41 | 39 | 39 | 44 | 40 | 40 | 34 | 32 | |
SBC by award type — Restricted stock units (RSUs) ($M)($M) | 85 | 75 | 74 | 84 | 85 | 71 | 66 | 66 | 67 | 55 | 27 | 43 | |
SBC by award type — Performance stock units (PSUs) ($M)($M) | 4 | 3 | 3 | 2 | 2 | 1 | -3 | 2 | 3 | 3 | |||
SBC by award type — Employee stock purchase plan (ESPP) ($M)($M) | 2 | 2 | 1 | 2 | 2 | 4 | 2 | 0 | 2 | 3 | 1 | 2 | |
SBC by function — Selling, general and administrative ($M)($M) | 43 | 37 | 41 | 44 | 42 | 39 | 30 | 37 | 39 | 34 | 28 | 30 | |
Total unrecognized stock-based compensation cost ($M)($M) | 831 | 978 | 633 | 770 | 908 | 1,100 | 820 | 875 | 1,000 | 1,200 | 835 | 701 | |
Industry benchmarks (FRED) — U.S. PPI: Pharmaceutical Preparation Manufacturing (Index)3 | 926.70 | 925.40 | 919.10 | 917.40 | 915.10 | 915.30 | 918.10 | 917.30 | 914.40 | 907.80 | 896.30 | 896.50 | |
U.S. Retail Sales: Pharmacies and Drug Stores, Seasonally Adjusted ($M)($M) | 97,481 | 95,519 | 103,201 | 102,234 | 100,190 | 98,467 | 97,365 | 95,992 | 89,716 | 87,927 | 89,673 | 85,816 | |
U.S. Retail Sales: Pharmacies and Drug Stores, Not Seasonally Adjusted ($M)($M) | 97,059 | 93,047 | 106,419 | 102,171 | 99,818 | 95,892 | 100,312 | 95,792 | 89,173 | 86,987 | 91,914 | 85,089 | |
U.S. Personal Consumption Expenditures: Health Care Services, SAAR ($B) | 3,790.30 | 3,699.90 | 3,667.00 | 3,614.80 | 3,529.80 | 3,464.70 | 3,417.80 | 3,358.20 | 3,288.20 | 3,244.40 | 3,159.40 | 3,079.00 | |
Income Statement — Total revenue ($M)($M)14 | 145 | 389 | 678 | 1,016 | 142 | 108 | 966 | 1,862 | 241 | 167 | 2,811 | 1,831 | |
Cost of sales ($M)($M) | 93 | 955 | 452 | 207 | 119 | 90 | 739 | 514 | 115 | 96 | 929 | 2,241 | |
Research and development expense ($M)($M) | 651 | 649 | 775 | 801 | 700 | 856 | 1,122 | 1,137 | 1,221 | 1,063 | 1,406 | 1,160 | |
Selling, general and administrative expense ($M)($M) | 216 | 173 | 308 | 268 | 230 | 212 | 351 | 281 | 268 | 274 | 470 | 442 | |
Total operating expenses ($M)($M) | 960 | 1,777 | 1,535 | 1,276 | 1,049 | 1,158 | 2,212 | 1,932 | 1,604 | 1,433 | 2,805 | 3,843 | |
Operating income (loss) ($M)($M) | -815 | -1,388 | -857 | -260 | -907 | -1,050 | -1,246 | -70 | -1,363 | -1,266 | 6 | -2,012 | |
Interest income ($M)($M) | 67 | 72 | 70 | 73 | 81 | 90 | 91 | 103 | 111 | 120 | 103 | 105 | |
Other non-operating income (expense), net ($M)($M) | -19 | -18 | -12 | 0 | 8 | -4 | -29 | -12 | -27 | -19 | -39 | -51 | |
Income (loss) before income taxes ($M)($M) | -767 | -1,334 | -799 | -187 | -818 | -964 | -1,184 | 21 | -1,279 | -1,165 | 70 | -1,958 | |
Provision for (benefit from) income taxes ($M)($M) | 15 | 9 | 27 | 13 | 7 | 7 | -64 | 8 | 0 | 10 | -147 | 1,672 | |
Net income (loss) ($M)($M) | -782 | -1,343 | -826 | -200 | -825 | -971 | -1,120 | 13 | -1,279 | -1,175 | 217 | -3,630 | |
Earnings (loss) per share — Basic ($/sh)($) | -1.97 | -3.40 | -0.51 | -2.13 | -2.52 | 0.03 | -3.33 | -3.07 | -9.53 | ||||
Earnings (loss) per share — Diluted ($/sh)($) | -1.97 | -3.40 | -0.51 | -2.13 | -2.52 | 0.03 | -3.33 | -3.07 | -9.53 | ||||
Weighted-average basic shares outstanding (M) | 398.00 | 395.00 | 390.00 | 388.00 | 386.00 | 385.00 | 384.00 | 382.00 | 381.00 | ||||
Weighted-average diluted shares outstanding (M) | 398.00 | 395.00 | 390.00 | 388.00 | 386.00 | 399.00 | 384.00 | 382.00 | 381.00 | ||||
Balance Sheet — Total assets ($M)($M)27 | 10,961 | 11,488 | 12,338 | 12,135 | 12,010 | 12,704 | 14,142 | 15,803 | 15,680 | 16,729 | 18,426 | 19,450 | |
Cash and cash equivalents ($M)($M) | 1,723 | 1,908 | 2,595 | 1,132 | 1,279 | 1,623 | 1,929 | 1,644 | 2,478 | 2,051 | 2,907 | 2,932 | |
Short-term marketable securities ($M)($M) | 3,415 | 3,297 | 3,204 | 3,372 | 3,852 | 4,352 | 5,098 | 5,223 | 6,010 | 6,472 | 5,697 | 4,641 | |
Accounts receivable, net ($M)($M) | 17 | 71 | 184 | 1,046 | 36 | 78 | 358 | 1,564 | 163 | 137 | 892 | 1,866 | |
Inventory, net ($M)($M) | 280 | 146 | 153 | 332 | 240 | 128 | 117 | 412 | 399 | 295 | 202 | 487 | |
Prepaid expenses and other current assets ($M)($M) | 380 | 348 | 408 | 716 | 764 | 585 | 599 | 823 | 611 | 645 | 627 | 873 | |
Total current assets ($M)($M) | 5,815 | 5,770 | 6,544 | 6,598 | 6,171 | 6,766 | 8,099 | 9,666 | 9,661 | 9,600 | 10,325 | 10,799 | |
Long-term marketable securities ($M)($M) | 1,772 | 2,251 | 2,336 | 2,143 | 2,374 | 2,418 | 2,494 | 2,335 | 2,326 | 3,638 | 4,677 | 5,273 | |
Property, plant and equipment, net ($M)($M) | 2,059 | 2,086 | 2,134 | 2,126 | 2,169 | 2,212 | 2,196 | 2,381 | 2,196 | 2,063 | 1,945 | 1,952 | |
Operating lease right-of-use assets ($M)($M) | 697 | 706 | 719 | 738 | 750 | 752 | 759 | 784 | 775 | 697 | 713 | 765 | |
Goodwill ($M)($M) | 52 | 52 | 52 | 52 | 52 | 52 | 52 | 52 | 52 | 52 | 52 | 52 | |
Intangible assets, net ($M)($M) | 109 | 116 | 45 | 47 | 48 | 49 | 40 | 41 | 42 | 43 | 44 | 45 | |
Deferred tax assets, non-current ($M)($M) | 82 | 82 | 81 | 81 | 81 | 81 | 81 | 81 | 81 | 81 | 81 | 0 | |
Other non-current assets ($M)($M) | 618 | 675 | 605 | 530 | 546 | 556 | 594 | 556 | 641 | 650 | 766 | 661 | |
Accounts payable ($M)($M) | 167 | 161 | 317 | 267 | 175 | 226 | 405 | 373 | 279 | 183 | 520 | 494 | |
Accrued liabilities ($M)($M) | 1,909 | 1,912 | 1,386 | 1,178 | 987 | 1,001 | 1,427 | 1,376 | 1,333 | 1,396 | 1,798 | 2,224 | |
Deferred revenue, current ($M)($M) | 295 | 102 | 99 | 163 | 218 | 125 | 153 | 379 | 702 | 559 | 568 | 1,372 | |
Operating lease liabilities, current ($M)($M) | 21 | 19 | 17 | 17 | 16 | 15 | 14 | 21 | 25 | 25 | 25 | 33 | |
Other current liabilities ($M)($M) | 163 | 220 | 185 | 73 | 192 | 252 | 221 | 69 | 42 | 190 | 129 | 239 | |
Total current liabilities ($M)($M) | 2,534 | 2,395 | 1,987 | 1,681 | 1,572 | 1,604 | 2,206 | 2,201 | 2,363 | 2,380 | 3,015 | 4,385 | |
Operating lease liabilities, non-current ($M)($M) | 638 | 645 | 653 | 660 | 666 | 667 | 671 | 679 | 668 | 637 | 643 | 697 | |
Deferred tax liabilities ($M)($M) | 255 | 253 | 249 | 239 | 237 | 234 | 231 | 241 | 235 | ||||
Other non-current liabilities ($M)($M) | 284 | 283 | 285 | 281 | 276 | 274 | 267 | 276 | 266 | 262 | 256 | 172 | |
Total liabilities ($M)($M) | 4,200 | 4,080 | 3,688 | 2,805 | 2,611 | 2,638 | 3,241 | 3,876 | 3,968 | 3,912 | 4,572 | 5,995 | |
Additional paid-in capital ($M)($M) | 1,644 | 1,503 | 1,382 | 1,254 | 1,127 | 982 | 866 | 751 | 631 | 487 | 371 | 277 | |
Retained earnings (accumulated deficit) ($M)($M) | 5,098 | 5,880 | 7,223 | 8,049 | 8,249 | 9,074 | 10,045 | 11,165 | 11,152 | 12,431 | 13,606 | 13,389 | |
Accumulated other comprehensive income (loss) ($M)($M) | 19 | 25 | 45 | 27 | 23 | 10 | -10 | 11 | -71 | -101 | -123 | -211 | |
Total stockholders' equity ($M)($M) | 6,761 | 7,408 | 8,650 | 9,330 | 9,399 | 10,066 | 10,901 | 11,927 | 11,712 | 12,817 | 13,854 | 13,455 | |
Cash Flow Statement — Operating cash flow ($M)($M)10 | -526 | -630 | 930 | -847 | -919 | -1,037 | 825 | -1,566 | -1,274 | -989 | 622 | -1,600 | |
Depreciation and amortization ($M)($M) | 56 | 56 | 66 | 51 | 56 | 38 | 59 | 51 | 40 | 35 | 203 | 246 | |
Stock-based compensation ($M)($M) | 120 | 104 | 113 | 125 | 130 | 115 | 104 | 112 | 112 | 101 | 79 | 77 | |
Change in deferred revenue ($M)($M) | 190 | 5 | -67 | 40 | 97 | -29 | -262 | -323 | 179 | -33 | -887 | -194 | |
Change in inventories ($M)($M) | -132 | 6 | 179 | -91 | -114 | -8 | 291 | -11 | -104 | -93 | 285 | 228 | |
Change in accounts receivable ($M)($M) | 53 | 114 | 859 | -1,013 | 30 | 280 | 1,206 | -1,401 | -26 | 755 | 974 | -1,634 | |
Change in accounts payable ($M)($M) | -8 | -120 | 22 | 89 | -47 | -156 | 34 | 96 | 104 | -303 | 21 | 179 | |
Capital expenditures ($M)($M) | 37 | 62 | 39 | 33 | 3 | 117 | 522 | 151 | 182 | 196 | 220 | 140 | |
Net cash provided by (used in) investing activities ($M)($M) | 329 | -76 | -48 | 700 | 564 | 730 | -539 | 721 | 1,649 | 118 | -538 | 789 | |
Net cash provided by (used in) financing activities ($M)($M) | 14 | 17 | 581 | -1 | 9 | 4 | -3 | 11 | 34 | 14 | -109 | -58 | |
Net increase (decrease) in cash, cash equivalents and restricted cash ($M)($M) | -185 | -688 | 1,463 | -147 | -345 | -303 | 282 | -833 | 409 | -857 | -25 | -869 | |
7 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Fiscal calendar & single-segment structure: Moderna, Inc. operates on a calendar fiscal year ending December 31 (FY2025 ended December 31, 2025; Q1 2026 ended March 31, 2026; Q2 2026 ended June 30, 2026) and manages its business as a single global operating segment focused on mRNA medicines. Operational performance is therefore tracked through product-level vaccine sales, quarterly geographic net product sales, gross-to-net (GTN) reserve rollforwards, Cost of Sales manufacturing utilization drivers, clinical pipeline counts, R&D investment by therapeutic modality, and strategic co-development collaborations.
- Core commercial, GTN & Cost of Sales KPIs (Groups 1–3) cover: (1) Commercial Respiratory Franchise & Geographic Net Product Sales ($1,831M in FY25 and $100M in Q2 2026 across COVID-19 vaccines Spikevax/mNEXSPIKE and RSV vaccine mRESVIA; 22 consecutive quarters of U.S., Europe, and Rest of World Net Product Sales disaggregation from Note 2 that are not in the standard segment database; U.S. retail pharmacy COVID-19 market share of 42% in FY25; 3 approved commercial products; and Stand-Ready Manufacturing revenue from sovereign mRNA facilities in the U.K., Canada, and Australia); (2) Gross-to-Net (GTN) Sales Reserves & APA Deferred Revenue ($3,262M gross product sales vs. -$1,431M GTN provisions in FY25, broken down into chargebacks/discounts and returns/rebates; $534M refund liability at Q2 2026; and $278M total deferred revenue across Advance Purchase Agreements and stand-ready contracts); and (3) Cost of Sales Drivers & Inventory by Stage ($868M Cost of Sales or 48% of net product sales in FY25, including $88M third-party royalties, $291M inventory write-downs, and $10M firm purchase commitment losses; $895M third-party royalties in Q1 2026 from the Arbutus/Genevant lipid nanoparticle litigation settlement; and $257M net inventory at Q2 2026 across Raw Materials, WIP, and Finished Goods).
- Pipeline, R&D, Facilities, Capital & ESG KPIs (Groups 4–7) cover: (4) Clinical Pipeline & R&D by Modality (36 development programs across 26 development candidates at Q2 2026; 146 Moderna-sponsored clinical studies / 137 interventional trials / ~255,600 cumulative participants tracked via ClinicalTrials.gov API v2; $3,117M GAAP R&D in FY25 disaggregated into Infectious Disease Vaccines $652M, Oncology $201M, Rare Diseases $43M, Discovery & Platform Research $356M, Technical Development & Manufacturing $792M, and Shared Discovery & Development $797M; plus Merck mRNA-4157 50/50 R&D cost-sharing and Blackstone Life Sciences influenza funding); (5) Manufacturing Footprint, PP&E & Commitments ($2,250M net PP&E at Q2 2026 across U.S., Europe, and Rest of World; 769,000 sq ft in Cambridge and 679,000 sq ft at the Norwood manufacturing campus; $933M supply & manufacturing and $681M clinical service minimum purchase obligations at FY25); (6) Cash & Marketable Securities Portfolio ($3,537M amortized cost at Q2 2026 across U.S. Treasury debt, corporate debt, money market funds, and CDs; $398M SBC in FY25 across options, RSUs, PSUs, and ESPP; and $6,080M gross DTA offset by a $6,000M valuation allowance at FY25); and (7) Workforce, Quality & ESG (4,700 full-time employees across 18 countries in FY25, 119:1 CEO pay ratio, 14 health authority inspections with 100% acceptable outcomes and 0 recalls in FY25, Scope 1–3 GHG emissions, energy, water, waste, and 0.25 TRIR).
- No parent-only standalone financial statements exist under U.S. GAAP (Form 10-K omits Schedule I), so no Consolidated − Standalone subtraction is performed. All values are strictly as published (with verbatim quotes on hover for text-extracted metrics). The only arithmetic shown in table cells is period splitting (Q4 = full year − 9M; Q2 = 6M − Q1; Q3 = 9M − 6M), displayed in italic with the formula.
Không hiện vì thiếu các kỳ gần đây (11)
- CDC / Our World in Data U.S. COVID-19 vaccine doses administered by manufacturer (Moderna vs. Pfizer): discontinued after May 2023 when the U.S. federal COVID-19 Public Health Emergency ended (fails the 3 recent continuous periods requirement).
- Commercial vaccine doses delivered / shipped (millions of doses): Moderna disclosed full-year doses delivered only during the 2021–2022 pandemic APA period (~807M doses in FY2021) and discontinued periodic dose volume reporting from FY2023 onward.
- Remaining Performance Obligations (RPO) / APA contract backlog ($B): disclosed intermittently in narrative notes (e.g., ~$4.2B in FY2025 10-K across multi-year horizons) without a consistent quarterly or annual point-in-time series across the last 3 quarters.
- Clinical trial efficacy rates, seroconversion percentages, and geometric mean titer (GMT) ratios for individual pipeline candidates (mRNA-1283, mRNA-1010, mRNA-1083, mRNA-4157, mRNA-1647, mRNA-1403): event-specific clinical trial readouts rather than recurring periodic operational time series.
- Scope 3 GHG emissions for FY2025: Moderna's 2025 Impacting Human Health Report published in April 2026 disclosed FY2021–FY2025 Scope 1 & 2 emissions, energy, water, and waste, while Scope 3 value-chain inventory is reported through FY2024 in the 2021–2024 Environmental Data table.
- FRED CPI Prescription Drugs series (CUUR0000SEMF01): returned HTTP error / HTML from FRED endpoint; replaced with active FRED CPI Medical Care Commodities (CUSR0000SAM1) and PPI Pharmaceutical Preparation Manufacturing (PCU325412325412).
- Approximate / bound-only disclosures ('more than 1,900 participants', 'over 1 billion doses', '>90% efficacy'): excluded per strict point-value rule (lib.quotes.is_bound).
- Self-computed ratios, margins, YoY/QoQ growth percentages, and component sums not explicitly published by Moderna: excluded per strict derivation rule (only Q4 = FY - 9M and Q = YTD - prior YTD period splits are permitted).
- Gross-to-Net (GTN) Sales Reserves, Customer Rebates & APA Deferred Revenue › Gross product sales (before gross-to-net variable consideration deductions) ($M) › Total gross-to-net (GTN) provisions & variable consideration deductions ($M) › GTN provision — Product returns, government rebates and refunds (legacy grouping) ($M)
- Industry & Healthcare Benchmarks (FRED) & Core Financial Statements (Database Baseline) › Industry benchmarks (FRED) — U.S. PPI: Pharmaceutical Preparation Manufacturing (Index) › U.S. CPI: Medical Care Commodities / Medicinal Drugs (Index, 1982–84=100)
- Industry & Healthcare Benchmarks (FRED) & Core Financial Statements (Database Baseline) › Industry benchmarks (FRED) — U.S. PPI: Pharmaceutical Preparation Manufacturing (Index) › U.S. CPI: Medical Care Services (Index, 1982–84=100)
Dữ liệu cập nhật 2026-11-03.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Commercial Respiratory Franchise (COVID-19 & RSV) & Geographic Revenue Disaggregation
Gross-to-Net (GTN) Sales Reserves, Customer Rebates & APA Deferred Revenue
Cost of Sales Drivers, Manufacturing Utilization Charges & Inventory by Stage
Clinical Pipeline, ClinicalTrials.gov Registry, R&D by Modality & Strategic Collaborations
- Development pipeline — Total active mRNA development programs (programs)29 kỳ
- ClinicalTrials.gov registry — Cumulative Moderna-sponsored studies (studies)34 kỳ
- Research and development expenses — Total GAAP ($M) ($M)34 kỳ
- Strategic collaborations — Merck (intismeran autogene / mRNA-4157) gross R&D incurred ($M) ($M)14 kỳ
- Strategic collaborations — Blackstone Life Sciences (influenza) funding recognized as contra-R&D ($M) ($M)10 kỳ
Manufacturing Footprint, PP&E by Asset Class, Leases & Purchase Commitments
Cash & Marketable Securities Portfolio, Share Repurchases, SBC & Tax Attributes
Human Capital, Executive Compensation, Regulatory Quality & Environmental Sustainability
- Global full-time employees at year-end (employees)8 kỳ
- CEO to median employee pay ratio (x) (×)6 kỳ
- Product quality & regulatory compliance — Total health authority inspections (inspections)5 kỳ
- Environmental sustainability — Scope 1 direct GHG emissions (tCO2e)5 kỳ
- Energy, water & waste — Direct energy consumption (MWh)5 kỳ
- Employee health & safety — Total Recordable Incident Rate (TRIR, per 200,000 hours)3 kỳ
Industry & Healthcare Benchmarks (FRED) & Core Financial Statements (Database Baseline)
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Moderna
See a number that looks wrong?